|
Apr 19, 2019, 07:20 AM
|
 |
|
|
Member Since: Dec 2018
Location: New Jersey
Posts: 6,008
|
|
This is correct. Drug companies use the previous year's prescription stats and try and project or estimate how many new ones there will be along with using the old data. Then they submit the request to the DEA which authorizes and supplies the raw ingredients to the manufacturers. In some cases the meds are produced "in house" meaning they are not outsourced to a third party company for production (out of the country in many cases). If they underestimate there is a shortage and (not surprisingly) the prices often increase. Overestimation and the prices often go down. Sometimes the inspections of imported medications or imported from outsourced medications delay things. And sometimes when patents expire and the company is waiting for approval to extend it affect things. Also sometimes the demand for the generic versions is high because they are cheaper. Sometimes if you have good insurance asking for the brand can circumvent the issue.
Quote:
Originally Posted by still_crazy
benzodiazepine prescribing is on the uptick in the US. each year, the DEA signs off on certain amounts of materials to produce controlled substances. if their estimates didn't keep up with prescribing habits, then there might be a shortage. this happened w/ stimulants a couple years ago... :-(
sorry about this. maybe its specific to certain benzodiazepines? lorazepam is popular, but id wager that xanax is still a bit more popular...maybe ask the pharmacy if they have other benzodiazepines in stock? other than that...
again, sorry about this.
|
__________________
"I carried a watermelon?"
President of the no F's given society.
|